BioAge appoints Dov Goldstein as Chief Financial Officer and Ann Neale as Chief Development Officer

Key Facts

RICHMOND, Calif.--()--BioAge Labs, Inc., a clinical-stage biotechnology company developing medications that target the molecular causes of aging to extend healthy human lifespan, today announced the appointment of Dov Goldstein, M.D., M.B.A. as Chief Financial Officer (CFO) and Ann Neale as Chief Development Officer (CDO).
From 2000 to 2005, he served as CFO of Vicuron Pharmaceuticals (acquired by Pfizer in 2005 for $1.9 billion), where he raised over $250 million in equity financing and played major roles in the company’s partnership transactions.
“I am impressed with the creative and practical foundation that BioAge has built in such a short time, as well as the company’s unique approach using the analytics platform to identify drug targets that impact aging.
By targeting the mechanisms of aging with a large and mechanistically diverse portfolio of drugs, BioAge will unlock opportunities to treat or even prevent these diseases in entirely new ways.